PTC Therapeutics Raises Revenue Guidance on Strong Sephience Sales
Event summary
- PTC Therapeutics reported Q2 2026 revenue of $361 million, with product revenue up over 100% YoY to $239 million.
- Sephience generated $151 million in Q2 2026 revenue, showing 21% growth from Q1 2026.
- Full-year 2026 revenue guidance raised to $1.18–$1.28 billion, with product revenue now expected at $850–$950 million.
- PTC received a $50 million milestone payment from Novartis for the INVEST-HD Phase 3 study initiation.
The big picture
PTC Therapeutics' strong Q2 performance reflects growing demand for its rare disease therapies, particularly Sephience. The company's strategic focus on pipeline advancement and regulatory milestones positions it to capitalize on unmet medical needs in specialized indications. With a robust cash position and expanding commercial footprint, PTC is well-positioned to sustain growth despite competitive pressures in the biopharmaceutical sector.
What we're watching
- Regulatory Milestones
- Whether PTC's planned FDA engagement in H2 2026 for votoplam will accelerate approval timelines.
- Pipeline Progress
- The pace at which PTC303 and PTC612 advance through clinical development for Huntington's disease and myotonic dystrophy.
- Commercial Momentum
- How Sephience's international expansion impacts revenue diversification beyond the US market.
Related topics